As a result of recent regulatory changes, the Committee on Foreign Investment in the United States (CFIUS) has become an area of increasing focus for life sciences companies. Navigating the requirements—and debunking the myths—of CFIUS rules is routinely becoming part of financings, mergers and other significant transactions. Life sciences companies often have investors, acquirers and partners that raise potential CFIUS concerns, and few life sciences transactions of any nature will be able to avoid addressing CFIUS in some manner.
In this webinar, WilmerHale panelists will discuss CFIUS from the perspectives of both life sciences companies and their investors. Specific topics will include the technical requirements of CFIUS and the new pilot program that began in November 2018, which brought the life sciences and biotech industry sectors under CFIUS’s list of “27 critical industries.” Speakers will also outline practical steps companies and investors can take to ease the diligence process and avoid complications, and review the political and policy elements of CFIUS and the evolving landscape.
*CLE credit is not available for those who watch webinar recordings.
